Cover Image
市場調查報告書

Latanoprost 的中國市場分析

Investigation Report on China Latanoprost Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 336267
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Latanoprost 的中國市場分析 Investigation Report on China Latanoprost Market, 2010-2019
出版日期: 2015年07月24日 內容資訊: 英文 30 Pages
簡介

Latanoprost 是前列腺素的選擇性受體促效劑,具有效降低眼壓的功能。中國在1999年上市,2004年開發了Latanoprost 眼藥。從那之後,中國的Latanoprost 市場急速成長,2013年為2527萬人民幣的市場規模,到2014年擴大到2640萬人民幣 (增加4.47%) ,2010∼214年的年複合成長率(CAGR) 也達到了24.02%。市場迅速成長的要素為人口高齡化的發展和青光眼患者的增加等。

本報告提供中國的Latanoprost 的市場相關分析、市場整體規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來市場趨勢預測(今後5年份)等調查評估。

第1章 Latanoprost 的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Latanoprost 市場概況

  • 中國國內的Latanoprost 的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Latanoprost 銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Latanoprost 市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Latanoprost 市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Latanoprost 的醫院用標準價格

  • Pfizer Manufacturing Belgium NV (商標名:Xalatan)
  • Pharmacia & Upjohn (Belgium) (商標名:Xalatan)
  • Lunan Better Pharmaceutical Co., Ltd (商標名:Telijie)

第7章 中國國內的Latanoprost 的主要製造商 (過去5年份)

  • Pfizer Manufacturing Belgium NV
  • Pharmacia & Upjohn (Belgium)
  • Lunan Better Pharmaceutical Co., Ltd
  • China Resources Zizhu Pharmaceutical Co., Ltd

第8章 中國的Latanoprost 市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1507275

Glaucoma is an irreversible eye disorder which can lead to blindness. According to the statistics published by WHO in 2005, glaucoma is the second-leading cause of blindness after cataract. The number of glaucoma patients around the world is 70 million and will reach 80 million by 2020. And 50% of blindness cases in the world are caused by glaucoma. According to epidemiological studies of eye disease, by Feb. 2015, 2.3% of people aged above 40 suffer from glaucoma, among which about 30% may become blind. And it is predicted that by 2020, there will be about 21 million glaucoma patients in China. Developed by Pharmacia & Upjohn in 1995, latanoprost is a selective prostaglandin receptor agonist which effectively reduces intraocular pressure. As the first pressure-lowering prostaglandin approved by FDA, latanoprost (under the trade name of Xalatan) entered China in 1999. In 2004, latanoprost eye drop developed by Lunan Better Pharmaceutical Co., Ltd was approved to be marketed, followed by products of Merro Pharmaceutical Co., Ltd, Hengrui Pharmaceutical and China Resources Zizhu Pharmaceutical Co., Ltd. Latanoprost has already become the first-line drug for the treatment of glaucoma.

Latanoprost develops fast after entering China, sales value rising from CNY 25.27 million in 2013 to CNY 26.40 million in 2014 with a year-on-year growth of 4.47% and CAGR during the period of 2010-2014 reaching 24.02%. With ageing population, the incidence of glaucoma continues to increase. Unlike cataract which can be treated with surgery, glaucoma provides a large market for conservative and postoperative medication. Therefore, latanoprost enjoys a vast demand in China. Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn (Belgium), Lunan Better Pharmaceutical Co., Ltd, China Resources Zizhu Pharmaceutical Co., Ltd and Pharmacia & Upjohn (Sweden) occupy the majority of the market share, among which Pfizer Manufacturing Belgium NV had the largest market share of about 43.1% for sales value in 2014. However, its market share was even larger i.e. 44.3% in 2013. Meanwhile, the market share of Pharmacia & Upjohn also decreased from 30.8% in 2013 to 29.5% in 2014. On the contrary, local manufacturers like Lunan Better Pharmaceutical Co., Ltd and China Resources Zizhu Pharmaceutical Co., Ltd both reported an increased market share (a 1.5% increase from 13.7% to 15.2% achieved by Lunan Better) in 2014 and will gain a larger share as biological technology develops further and they come to know more about domestic drugs.

Readers can get at least the following information from this report:

  • market size of latanoprost in China
  • major manufacturers of latanoprost in Chinese market
  • retail price of latanoprost in China
  • market outlook of latanoprost in China

The author suggests the following groups of people purchase this report:

  • manufacturers of ophthalmic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Latanoprost

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Latanoprost in China

  • 2.1. Patent Status and Approval Information of Latanoprost in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Latanoprost in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Latanoprost in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Latanoprost in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Latanoprost in Chinese Hospitals in 2014

  • 6.1. Pfizer Manufacturing Belgium NV (Trade Name: Xalatan)
  • 6.2. Pharmacia & Upjohn (Belgium) (Trade Name: Xalatan)
  • 6.3. Lunan Better Pharmaceutical Co., Ltd (Trade Name: Telijie)

7. Major Manufacturers of Latanoprost in Chinese Market, 2010-2014

  • 7.1. Pfizer Manufacturing Belgium NV
  • 7.2. Pharmacia & Upjohn (Belgium)
  • 7.3. Lunan Better Pharmaceutical Co., Ltd
  • 7.4. China Resources Zizhu Pharmaceutical Co., Ltd

8. Market Outlook of Latanoprost in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Latanoprost in China
  • Chart Approval Information of Latanoprost in China
  • Chart Sales Status of Latanoprost in China
  • Chart Sales Value of Latanoprost in China, 2010-2014
  • Chart Sales Value of Latanoprost in Some Regions in China, 2010-2014
  • Chart Sales Volume of Latanoprost in China, 2010-2014
  • Chart Sales Volume of Latanoprost in Some Regions in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Latanoprost for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Latanoprost Made by Pfizer Manufacturing Belgium NV in China, 2010-2014
  • Chart Sales Value and Market Share of Latanoprost Made by Pharmacia & Upjohn (Belgium) in China, 2010-2014
  • Chart Sales Value and Market Share of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Latanoprost Made by Other Manufacturers in China, 2010-2014
  • Chart Price of Latanoprost Made by Pfizer Manufacturing Belgium NV in Some Chinese Cities in 2014
  • Chart Price of Latanoprost Made by Pharmacia & Upjohn (Belgium) in Some Chinese Cities in 2014
  • Chart Price of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top